The United Kingdom and the United States have concluded a significant trade agreement that will maintain no tariffs on UK drug exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on medicines through the NHS. This pledge ensures that duties on these crucial goods will be held at zero for a period of three years.
This deal comes after earlier warnings to hike duties on patented drug imports, with potential rates discussed reaching 100%.
"This arrangement between the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed equity to American-British medicine commerce," an announcement said.
Commercial Significance
Medicines represent one of the the United Kingdom's largest exports to the America, which is easily the largest market for major British pharmaceutical firms.
Trade data reveal that in the year prior to the third quarter, the UK sold medicines worth £11.1bn to the US. This amount represented a significant portion of total UK exports in that span.
"This agreement safeguards jobs, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister stated.
Specific British Pledges
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase overall public funding on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The sum drug companies must return to the NHS to control costs will be restricted at fifteen percent. Last year, repayments topped 20%.
Broader Context
The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were intensified by arguments that US customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while major funding commitments have been directed toward American operations.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the past decade.
